Latest news for Evergold (OTC:EVGUF) Stock

Evergold Corp is engaged in the exploration and development of mineral properties in British Columbia, Canada. The company's projects include Snoball, Golden Lion, Spanish Lake, Snoball and Holy Cross.

Evergold Corp

WIIM

SPOT

Spotify shares are trading higher after Pivotal Research raised its price target on the stock from $460 to $510.

Stablecoins have emerged as a significant force in the global financial landscape, reaching new heights in circulation and usage, according to a recent report <a href="https://benzinga.com/z/40879982">by Bernstein analysts</a>.
What Happened: The total supply of stablecoins has rebounded to an all-time high of $170 billion, with monthly settlement volumes tripling over the last 12 months to $1.4 trillion in July 2024. This growth underscores stablecoins&#8217; increasing importance in the crypto ecosystem and beyond.
&#8220;Stablecoins are becoming systemically important &#8211; now 18th largest holder of U.S treasury along with large sovereign holders,&#8221; the analysts noted. They highlighted stablecoins&#8217; role in providing USD savings access to international users and serving as the primary base currency for crypto trading.
Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) remains the dominant player with $120 billion in circulation, followed by Circle&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) at $35 billion. The analysts attributed Tether&#8217;s lead to its integration with global offshore exchanges and cross-border payments usage in non-US markets.
Bernstein rated Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) an Outperform with a price target of $30 as it expects the platform to continue integrating stablecoins for crypto trading &amp; cross-border transfers. Robinhood has <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39204424/robinhood-announces-acquisition-of-crypto-exchange-bitstamp-in-200m-deal">recently acquired</a> the international crypto exchange Bitstamp.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40922909/revolut-plans-to-launch-stablecoin-crypto-is-part-of-our-belief-in-banking-without-borders">Revolut Plans To Launch Stablecoin: &#8216;Crypto Is Part Of Our Belief In Banking Without Borders&#8217;</a>
Why It Matters: Interestingly, stablecoin adoption appears to be decoupling from overall crypto market volatility. Monthly active wallets holding stablecoins have consistently risen to 22 million, despite fluctuations in trading volumes. This suggests growing usage beyond just crypto trading.
The report also highlighted the emergence of new players in the stablecoin space, including PayPal&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PYUSD</a>), which has reached nearly $1 billion in circulation since its launch.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) continues to dominate stablecoin transaction volume, accounting for about 45% of total transfers.
Perhaps most notably, the analysts found that younger demographics, particularly in emerging markets, are embracing stablecoins as a store of value. "20% of 18-24-year-olds (in emerging markets) hold 25-50% of their portfolio in stablecoins," the report stated, indicating a growing trend of using stablecoins as an alternative to local currencies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40890517/trump-introduces-world-liberty-financial-aims-to-encourage-stablecoin-adoption-with-sons-l">Trump Introduces &#8216;World Liberty Financial,&#8217; Aims To Encourage Stablecoin Adoption With Sons Leading The Charge: &#8216;Crypto Is One Of Those Things We Have To Do&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$ETH

$PYUSD

$USDC

$USDT

HOOD

Stablecoins Like Tether 'Becoming Systemically Important': Bernstein

Macro Notification

General

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

White House Says U.S. Unwavering Against All Iran-Backed Threats, Including Hezbollah; Diplomatic Solution Is Achievable, It Is Urgent; Believe A Ceasefire Deal For Gaza Would Lower Temperature In The Region; Will Continue To Work On Alternative Diplomatic Solutions To Allow Displaced Civilians To Go Home

Artificial intelligence may be a useful tool <a href="https://www.benzinga.com/news/large-cap/24/09/40942266/amazon-launches-ai-assistant-codenamed-project-amelia">for financial advisors</a>, but it will not solve their every problem.
There are three ways that financial advisors can use AI to their utmost benefit, AssetMark and Wealthmanagement.com say in a report: optimizing lead generation, segmenting the market and improving client communication.
<h2 class="wp-block-heading">Lead Generation</h2>
AI tools have proven to increase lead generation by as much as 50% and lower costs by as much as 60%, the report said.
&#8220;AI tools can build profiles based on names, publicly available data, and data from third-party vendors,&#8221; the report stated.
&#8220;These profiles can be compared to metrics for successful conversions, helping advisors focus attention on prospects who are more likely to become high-value clients.&#8221; 
<h2 class="wp-block-heading">Improved Market Segmentation</h2>
AI also helps to further segment prospects based on their unique needs, the report said.
AI and predictive analytics can also help financial advisors to quickly and accurately segment their clients based on their attributes, such as assets under management, demographics and profession.
&#8220;AI tools also help identify patterns and trends advisors can use to better understand their clients' needs and preferences,&#8221; the report said.
Read Also: <a href="https://www.benzinga.com/top-stories/24/09/40937593/oracle-cloudworld-highlights-ai-driven-tech-services-but-revenue-growth-requires-patience-analyst">Oracle CloudWorld Highlights &#8216;AI-Driven Tech Services,&#8217; But Revenue Growth Requires Patience: Analyst</a>
The ability to predict client behavior and preferences enables financial advisors to further use AI to create targeted marketing campaigns and messaging that resonate with their audience,&#8221; the report said.
&#8220;Segmentation can help advisors identify potential high-value clients, allowing them to pursue leads strategically and allocate their marketing resources more efficiently by aligning them with key growth drivers.&#8221;
<h2 class="wp-block-heading">Better Communication</h2>
AI tools can also help advisors to prioritize and target their communications with their clients, the report said.
&#8220;Predictive tools help advisors reach out to clients proactively to provide solutions at the right time — sometimes even before clients realize they need them,&#8221; it said.
&#8220;Getting the right information to the right clients at the right time is often the key to ensuring clients take action.&#8221;
AI can also give advisors a hand at creating engaging content for clients and also help them to write emails, social media content and website copy for clients more efficiently.
&#8220;Advisors can gather questions from clients, for instance, and use AI to generate custom content based on their inquiries that are specific to niche client needs,&#8221; the report said.
<h2 class="wp-block-heading">AI Tools &#8216;May Be Useful To Some Extent&#8217;</h2>
But AI is not the end-all, be-all solution for financial advisors, Canadian financial planner Jason Pereira <a href="https://www.kitces.com/blog/generative-ai-artificial-intelligence-advisor-technology-chat-gpt-software-innovation/">wrote</a> for Kitces.
&#8220;It may be helpful for advisors to take a realistic approach to the value that AI tools will provide, especially in an environment where technology providers often make bold claims about their solutions&#8217; ability to save time and reduce costs,&#8221; he wrote.
&#8220;Some of the capabilities of today&#8217;s AI tools (e.g., automating workflows or retrieving client information using a chatbot) may be useful to some extent, but if the processes that they replace don&#8217;t take that much time to begin with, then the tools&#8217; benefits may not justify the additional cost to implement them.&#8221;
It will most likely take 10 years for AI tools to develop to the point where they can help financial advisors in a meaningful way, such as reducing headcount by 50%, he said.
Price Action: Financial Advisory firms trended upward into Thursday&#8217;s mid-afternoon trading.
<ul>
<li>Franklin Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) went up 2.1% to $20.82.</li>
<li>Invesco Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INV#NYSE">INV</a>) gained 3.1% to $17.27</li>
<li>T. Rowe Price Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) picked up 2.45% to $110.78</li>
<li>AllianceBernstein Holding L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) gained 1.68% to $35.18</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40942923/short-seller-targets-verint-systems-stock-as-ai-threat-emerges-the-future-is-certainly-not-verint">Short Seller Targets Verint Systems Stock As AI Threat Emerges: &#8216;The Future Is Certainly Not Verint&#8217;</a></li>
</ul>
Image: Midjourney

Tech

TROW

Top 3 AI Uses For Financial Advisors Flagged In Report: Financial Planner Says Beware, Technology Is No Cure-All

PYPL

PayPal shares are trading higher amid overall market strength following the Fed's rate cut.

Guidance

RACE

STLA

TSLA

Mercedes-Benz Group Lowers 2024 FY Guidance: Adjusted Return On Sales For Mercedes-Benz Cars Now 7.5%-8.5%, FY EBIT And Free Cash Flow Expected To Be Significantly Below Prior Year Levels; Mercedes-Benz Vans Guidance Unchanged At 14%-15% Return On Sales

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">trading higher on Thursday</a>. Nio&#8217;s Onvo currently has 180 store managers in China, with 40% hailing from Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and 27% from Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), according to Xia Qinghua, head of Onvo&#8217;s user and service operations, CnEV Post <a href="https://cnevpost.com/2024/09/19/nio-onvo-40-pct-store-managers-from-tesla/" target="_blank" rel="noreferrer noopener">reports</a>.
The competition stories between NIO and Tesla is not new! Earlier this May, NIO reportedly reached an agreement with larger competitor BYD Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) to obtain batteries for a new EV brand positioned in a lower price range, targeting competition with Tesla, according to a Reuters report.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40937424/why-tesla-stock-is-rallying-about-3-higher-in-thursdays-premarket" rel="noreferrer noopener">Why Tesla Stock Is Rallying About 3% Higher In Thursday&#8217;s Premarket</a>
Meanwhile, Onvo is officially set to launch the L60 later today. The L60 first appeared on May 15 and opened for pre-orders at a promotional price of RMB219,900, which includes the battery.
This price is RMB30,000 lower than the current Tesla Model Y starting price in China.
Qinghua started a 20,000-kilometer long-distance journey across China in an Onvo L60 on August 15, shortly after the first production vehicle was completed.
He shared these details during a conversation with Nio founder, chairman, and CEO William Li while in the car, near the conclusion of the trip today, CnEV Post added.
Onvo opened its first 105 stores in China on September 1, and the total number of stores has now reached 120.
Price Action: NIO shares are trading higher by 6.87% to $5.37 at the last check on Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40939931/darden-restaurants-posts-q1-results-joins-tesla-nvidia-xpeng-and-other-big-stocks-moving-higher-on-t" target="_blank" rel="noreferrer noopener">Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday</a></li>
</ul>
Photo via Shutterstock

Equities

Emerging Markets

Markets

Movers

BYDDY

China's NIO Says 40% Of Its Store Managers Are Ex-Tesla

ALGS

Aligos Therapeutics shares are trading lower. The company announced results from its Phase 2a HERALD study.

<a href="https://ml-eu.globenewswire.com/Resource/Download/a99f35a4-13fc-4768-917a-94f1efa6e65f" title="https://ml-eu.globenewswire.com/Resource/Download/a99f35a4-13fc-4768-917a-94f1efa6e65f">https://ml-eu.globenewswire.com/Resource/Download/a99f35a4-13fc-4768-917a-94f1efa6e65f</a>

Wegovy Receives Positive Opinion From European Regulators For Label Update To Reflect Reduced Heart Failure Symptoms And Improved Physical Function In Obesity-Related HFpEF, Based On STEP HFpEF Trials Results

Analysts' ratings for Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.5, a high estimate of $154.00, and a low estimate of $137.00. This upward trend is evident, with the current average reflecting a 6.78% increase from the previous average price target of $135.33.
<img src="https://www.benzinga.com/files/images/story/2024/1726772841_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Sun Communities among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$154.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$149.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$144.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$138.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$131.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sun Communities. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Sun Communities compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sun Communities's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sun Communities's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sun Communities analyst ratings.</a>
<h2>Get to Know Sun Communities Better</h2>
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 351 manufactured housing communities, 179 residential vehicle communities, and 136 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
<h3>Financial Insights: Sun Communities</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Sun Communities's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.09% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: Sun Communities's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 6.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.75%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sun Communities's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.3%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.14, Sun Communities adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Glimpse Into The Expert Outlook On Sun Communities Through 6 Analysts

Deep-pocketed investors have adopted a bullish approach towards Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in KO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Coca-Cola. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 20% bearish. Among these notable options, 2 are puts, totaling $68,412, and 8 are calls, amounting to $357,313.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $85.0 for Coca-Cola over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Coca-Cola's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Coca-Cola's whale activity within a strike price range from $50.0 to $85.0 in the last 30 days. 
<h3>Coca-Cola Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726772749_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$14.05</td>
<td>$13.95</td>
<td>$13.95</td>
<td>$57.50</td>
<td>$73.9K</td>
<td>2.2K</td>
<td style="text-align: right;">161</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.01</td>
<td>$1.99</td>
<td>$2.01</td>
<td>$72.50</td>
<td>$62.9K</td>
<td>7.5K</td>
<td style="text-align: right;">428</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.5</td>
<td>$11.45</td>
<td>$11.5</td>
<td>$60.00</td>
<td>$59.8K</td>
<td>9.7K</td>
<td style="text-align: right;">292</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.55</td>
<td>$11.5</td>
<td>$11.55</td>
<td>$60.00</td>
<td>$46.2K</td>
<td>9.7K</td>
<td style="text-align: right;">336</td>
</tr>
<tr>
<td>KO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.75</td>
<td>$13.55</td>
<td>$13.65</td>
<td>$85.00</td>
<td>$38.2K</td>
<td>16</td>
<td style="text-align: right;">28</td>
</tr>
</tbody>
</table>

<h3>About Coca-Cola</h3>
Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around two thirds of its total revenue overseas, with a significant portion from emerging economies in Latin America and Asia-Pacific.
Having examined the options trading patterns of Coca-Cola, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Coca-Cola</h3>
<ul>
<li>Trading volume stands at 7,598,639, with KO's price down by -1.37%, positioned at $70.77.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 33 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Coca-Cola with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Coca-Cola Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $201,232, and 2 are calls, for a total amount of $119,247.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $280.0 to $370.0 for Amgen over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $280.0 to $370.0 over the preceding 30 days.
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726772744_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.55</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$370.00</td>
<td>$78.2K</td>
<td style="text-align: right;">649</td>
<td style="text-align: right;">80</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$7.1</td>
<td>$5.55</td>
<td>$6.3</td>
<td>$335.00</td>
<td>$48.5K</td>
<td style="text-align: right;">628</td>
<td style="text-align: right;">46</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$59.45</td>
<td>$58.55</td>
<td>$58.55</td>
<td>$280.00</td>
<td>$40.9K</td>
<td style="text-align: right;">89</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$14.3</td>
<td>$14.2</td>
<td>$14.2</td>
<td>$315.00</td>
<td>$39.7K</td>
<td style="text-align: right;">607</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$3.45</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$332.50</td>
<td>$32.5K</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Amgen</h3>
<ul>
<li>Currently trading with a volume of 759,929, the AMGN's price is up by 1.08%, now at $336.52. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 40 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

AMGN

Behind the Scenes of Amgen's Latest Options Trends

Investors with a lot of money to spend have taken a bullish stance on United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with UPS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 18 uncommon options trades for United Parcel Service.
This isn't normal.
The overall sentiment of these big-money traders is split between 66% bullish and 22%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $98,982, and 16 are calls, for a total amount of $1,038,170.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $145.0 for United Parcel Service, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for United Parcel Service's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Parcel Service's whale activity within a strike price range from $105.0 to $145.0 in the last 30 days. 
<h3>United Parcel Service 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726772739_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$9.4</td>
<td>$9.0</td>
<td>$9.0</td>
<td>$135.00</td>
<td>$282.3K</td>
<td>2.2K</td>
<td>302</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$2.4</td>
<td>$2.3</td>
<td>$2.3</td>
<td>$135.00</td>
<td>$142.3K</td>
<td>12.1K</td>
<td>4.9K</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$2.3</td>
<td>$2.29</td>
<td>$2.3</td>
<td>$135.00</td>
<td>$74.0K</td>
<td>12.1K</td>
<td>5.6K</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$2.63</td>
<td>$2.33</td>
<td>$2.57</td>
<td>$135.00</td>
<td>$67.9K</td>
<td>12.1K</td>
<td>797</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$2.63</td>
<td>$2.46</td>
<td>$2.61</td>
<td>$135.00</td>
<td>$67.3K</td>
<td>12.1K</td>
<td>532</td>
</tr>
</tbody>
</table>

<h3>About United Parcel Service</h3>
As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 64% of total revenue while international package makes up 20%. Air and ocean freight forwarding, truckload brokerage, and contract logistics make up the remainder. UPS is currently pursuing "strategic alternatives" for its truck brokerage unit, Coyote, which it acquired in 2015.
Having examined the options trading patterns of United Parcel Service, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of United Parcel Service</h3>
<ul>
<li>With a volume of 2,235,994, the price of UPS is up 1.68% at $132.85. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>What The Experts Say On United Parcel Service</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $144.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from TD Cowen lowers its rating to Hold with a new price target of $144.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for United Parcel Service, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

United Parcel Service's Options Frenzy: What You Need to Know

16 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of $600.00, and a low estimate of $376.00. Surpassing the previous average price target of $467.40, the current average has increased by 8.77%.
<img src="https://www.benzinga.com/files/images/story/2024/1726772730_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Vertex Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$431.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$510.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$508.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$509.00</td>
<td>$472.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$558.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$535.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Sell</td>
<td>$376.00</td>
<td>$371.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$455.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Steve Chesney</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$545.00</td>
<td>-</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$555.00</td>
<td>$540.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vertex Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vertex Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Vertex Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Discovering Vertex Pharmaceuticals: A Closer Look</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Vertex Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.11% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -135.83%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -21.57%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.32%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRTX

Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews

UBS analyst John Sourbeer upgrades QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) from Sell to Neutral and raises the price target from $42 to $50.

Upgrades

Price Target

QDEL

UBS Upgrades QuidelOrtho to Neutral, Raises Price Target to $50

Filecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/fil/usd">FIL</a>) price has increased 6.55% over the past 24 hours to $3.72. Over the past week, FIL has experienced an uptick of over 3.0%, moving from $3.64 to its current price. As it stands right now, the coin's all-time high is $236.84. 
The chart below compares the price movement and volatility for Filecoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726772620_0.png" alt="price_chart" />
The trading volume for the coin has increased 64.0% over the past week while the overall circulating supply of the coin has increased 0.32% to over 586.47 million which makes up an estimated 29.92% of its max supply, which is 1.96 billion. The current market cap ranking for FIL is #45 at $2.18 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726772620_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$FIL

Cryptocurrency Filecoin's Price Increased More Than 6% Within 24 hours

In the last three months, 4 analysts have published ratings on World Kinect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WKC#NYSE">WKC</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated World Kinect and provided 12-month price targets. The average target is $30.0, accompanied by a high estimate of $33.00 and a low estimate of $27.00. This current average reflects an increase of 3.45% from the previous average price target of $29.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726772617_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive World Kinect. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Royall</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Ken Hoexter</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to World Kinect. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of World Kinect compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of World Kinect's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WKC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on World Kinect analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About World Kinect</h2>
World Kinect Corp is a energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers . It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. Company operate in three reportable segments consisting of aviation, land, and marine. Company earn majority of revenue from Aviation segment.
<h3>Financial Milestones: World Kinect's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, World Kinect faced challenges, resulting in a decline of approximately -0.14% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: World Kinect's net margin excels beyond industry benchmarks, reaching 0.99%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): World Kinect's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.51%, the company showcases effective utilization of assets.
Debt Management: World Kinect's debt-to-equity ratio is below the industry average at 0.43, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For World Kinect

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.0, with a high estimate of $25.00 and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 2.33% from the previous average price target of $21.50.
<img src="https://www.benzinga.com/files/images/story/2024/1726772608_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Cibus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Venezia</td>
<td>Alliance Global Partners</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cibus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cibus compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Cibus's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Cibus's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CBUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cibus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Cibus</h2>
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
<h3>Cibus: A Financial Overview</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Cibus showcased positive performance, achieving a revenue growth rate of 325.38% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cibus's net margin is impressive, surpassing industry averages. With a net margin of -3398.33%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cibus's ROE excels beyond industry benchmarks, reaching -10.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Cibus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -5.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Cibus's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBUS

Expert Ratings For Cibus

CWA Says NY Times Tech Guild Authorized Strike With 95% In Favor

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), noting the company as a versatile large-cap with an attractive valuation.
Abbott has a diversified business model with solid distribution across segments (medtech, diagnostics, nutrition, pharmaceuticals) and geography. Medical devices are the company&#8217;s largest business, accounting for around 44% of total sales.
Abbott Laboratories&nbsp;reported second-quarter sales of $10.38 billion, up 4%, almost in line with the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.37 billion</a>.
Organic sales growth for the underlying base business was 9.3%, led by double-digit&nbsp;growth <a href="https://www.benzinga.com/24/07/39839507/abbott-laboratories-q2-earnings-revenue-and-profit-beat-estimates-nudges-up-annual-profit-guidance-o" target="_blank" rel="noreferrer noopener">in medical devices</a>.
Piper Sandler noted that the company struck a solid balance by achieving above-average growth for a large-cap medtech firm, maintaining strong efficiency metrics, and consistently paying dividends to shareholders.
Abbott has positioned itself as a high-single-digit growth company, placing it near the top of the large-cap medtech sector. Its medtech division has consistently contributed to overall growth, with expectations for double-digit expansion from 2024 to 2026.
Analyst Adam C. Maeder initiated coverage with an Overweight rating and a <a href="https://www.benzinga.com/quote/ABT/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $131</a>.
Talking about the valuation, the analyst highlighted that Abbott&#8217;s stock is currently valued at 22.3 times the consensus adjusted EPS estimates for 2025, reflecting a notable discount compared to its large-cap medtech peers.
This discount is partly driven by ongoing necrotizing enterocolitis (NEC) litigation, but the analyst contends that Abbott should still be trading at least on par with its peers, given its strong revenue growth and adjusted EPS outlook.
In July, Abbott stock fell following a U.S. jury&#8217;s ruling that found Abbott&#8217;s formula was responsible for a girl developing a severe bowel disease, leading to a hefty $495 million penalty. This verdict is part of nearly 1,000 lawsuits filed against Abbott Labs, its British rival&nbsp;Reckitt Benckiser Group PLC &#8211; ADR&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RBGLY#OTC">RBGLY</a>), both in U.S.<a href="https://www.benzinga.com/general/biotech/24/07/40006590/abbott-laboratories-tumble-nearly-8-in-pre-market-after-us-jury-charges-495m-penalty-for-disease-" target="_blank" rel="noreferrer noopener"> federal or state courts</a>.
&#8220;We don&#8217;t see much topline risk associated with the litigation, and we believe the Street is already pricing potential damages into the stock,&#8221; the analyst added.
ABT Price Action: Abbott Laboratories stock is down 1.07% at $113.66 at last publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40943923/theratechnologies-faces-potential-supply-disruption-for-its-top-selling-drug-warns-of-revenue-imp" target="_blank" rel="noreferrer noopener">Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays</a>.</li>
</ul>
Photo: Abbott

Analyst Color

Biotech

Large Cap

Health Care

Initiation

RBGLY

Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst

Evergold Corporation (TSE:EVER) has released an update. Evergold Corporation has completed a geophysical survey on the DEM1 prospect in central B.C...

Evergold Unveils Promising DEM1 Prospect for Drilling

Evergold Corporation (TSE:EVER) has released an update. Evergold Corporation has issued a news release that is incomprehensible due to formatting e...

Evergold Corporation Release: Unreadable Content

Evergold Corp (TSE:EVER) has released an update. Evergold Corp. has successfully raised $1,072,000 through the first tranche of a non-brokered priv...

Evergold Corp Secures Funding for Promising BC Drill Projects

Evergold Corp (TSE:EVER) has released an update. Evergold Corp. gears up for an exciting exploration season at their DEM property, located in centr...

Evergold Ramps Up Exploration at Central B.C. Prospect

Evergold Corp (TSE:EVER) has released an update. Evergold Corp. has received approval to extend the closing of the second tranche of its non-broker...

Evergold Corp Announces Financing Extension

Evergold Corp (TSE:EVER) has released an update. Evergold Corp. is gearing up for an ambitious fall drill program at their DEM1 prospect in central...

Evergold Corp. Sets Stage for Fall Drilling at B.C. Gold Prospect

Evergold Corp (TSE:EVER) has released an update. Evergold Corp. has initiated an ambitious drilling program at its DEM prospect in Central B.C., bu...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Evergold

News

Latest news for Evergold (OTC:EVGUF) Stock